Gemcitabine-related pulmonary toxicity

Publication

Gemcitabine-related pulmonary toxicity

Journal Paper/Review - Jan 12, 2002

Jörger Markus, Gunz A, Speich R, Pestalozzi Bernhard C

Citation

Jörger M, Gunz A, Speich R, Pestalozzi B. Gemcitabine-related pulmonary toxicity. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2002; 132:17-20.

Type

Journal Paper/Review (English)

Journal

Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2002; 132

Publication Date

Jan 12, 2002

Issn Print

1424-7860

Pages

17-20

Brief description/objective

BACKGROUND: Gemcitabine is an increasingly used and generally well tolerated anticancer drug. Rarely, it leads to potentially fatal pulmonary toxicity. CASE DESCRIPTIONS AND RESULTS: We describe the clinical features of 5 patients with gemcitabine-related pulmonary toxicity. Due to early diagnosis, prompt discontinuation of the drug, and treatment with steroids, toxicity was reversible in all cases. CONCLUSION: Early recognition of gemcitabine-related pulmonary toxicity is mandatory.